Begin typing your search above and press return to search.
NEETs credibility must be restored
access_time 14 Jun 2024 11:33 AM GMT
May peace prevail in West Asia
access_time 13 Jun 2024 5:29 AM GMT
The scholar and the ignoramus
access_time 12 Jun 2024 8:08 AM GMT
Modi cabinet
access_time 11 Jun 2024 12:41 PM GMT
Homechevron_rightIndiachevron_rightIntranasal Covid 19...

Intranasal Covid 19 vaccine from Bharat Biotech to cost Rs 800 for private sale

Intranasal Covid 19 vaccine from Bharat Biotech to cost Rs 800 for private sale

New Delhi: Bharat Biotech International Limited said on Tuesday that the pricing of its covid-19 intranasal vaccine, iNCOVACC, which is now offered on the CoWIN portal, is Rs 800 (excluding GST) for private markets and Rs 325 (excluding GST) for supplies to the government.

According to a press release from the vaccine producer, the jab will be available for administration from the fourth week of January 2023.

iNCOVACC is the world's first intranasal vaccine for covid to receive approval for the primary two-dose schedule and as a heterologous booster dose.

Earlier this month, Bharat Biotech received approval from the Central Drugs Standard Control Organisation (CDSCO) for the use of heterologous booster doses of iNCOVACC.

Krishna Ella, Executive Chairman of BBIL, said: "We have developed Covaxin and iNCOVACC, two covid vaccines from two different platforms, with two different delivery systems. The vectored intranasal delivery platform gives us the capability for rapid product development, scale-up, easy and painless immunisation during public health emergencies and pandemics".

Phase-III trials of iNCOVACC (as a two-dose regimen) were conducted for safety, and immunogenicity in approximately 3100 subjects, in 14 trial sites across India while Heterologous booster dose studies were conducted for safety and immunogenicity in 875 subjects, the release further said.

iNCOVACC was developed in partnership with Washington University, St Louis, which had designed and developed the recombinant adenoviral vectored construct and evaluated it in pre-clinical studies for efficacy, it added.

With PTI inputs

Show Full Article
TAGS:Covid 19Bharat BiotechVaccinationIntranasal
Next Story